How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

285 results for

Baclofen Withdrawal

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Withdrawal Syndromes (Diagnosis)

a benzodiazepine or phenobarbital, in a maintenance dose for a few days followed by a gradually decreasing dose over 2-3 weeks. GHB withdrawal can initially be treated with high doses of benzodiazepines, though anecdotally, refractory cases have responded to other sedative agents, such as pentobarbital, chloral hydrate, and baclofen. Opioid withdrawal is treated with a long-acting opioid agonist, such as methadone 20-35 mg/d or buprenorphine 4-16 mg/d, and then tapered over days to weeks. Clonidine 0.1-0.2 mg (...) , Champ-Rigot L, Labombarda F. Takotsubo cardiomyopathy triggered by alcohol withdrawal. Drug Alcohol Rev . 2011 Jul. 30(4):434-7. . Otero-Anton E, Gonzalez-Quintela A, Saborido J, Torre JA, Virgos A, Barrio E. Prolongation of the QTc interval during alcohol withdrawal syndrome. Acta Cardiol . 1997. 52(3):285-94. . LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care . 2008. 8(3):430-3. . . Ghio L, Cervetti A, Respino M, Belvederi Murri M, Amore M. Management

2014 eMedicine Emergency Medicine

62. Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis

Efficacy and Safety of Baclofen ER Capsules (GRS) in Subjects With Spasticity Due to Multiple Sclerosis Efficacy and Safety of SPARC0921 in Subjects With Spasticity - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) of subjects who become a treatment failure during double-blind randomized withdrawal [ Time Frame: Week 22 ] Determining the safety profile when administered over >12 weeks [ Time Frame: Week 22 ] Secondary Outcome Measures : Subject Global Impression of Severity (SGIS)assessment [ Time Frame: Week 22 ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about

2011 Clinical Trials

63. Benzodiazepines may protect against seizures in alcohol withdrawal syndrome

. Such an overview has recently been made available to bring together all of the Cochrane reviews that assess the effectiveness and safety of pharmacological interventions in the treatment of alcohol withdrawal. The overview brings together results from 5 Cochrane reviews, containing 114 studies and 7,333 participants in total. The treatments included in the overview are: Benzodiazepines Psychotropic analgesic nitrous oxide Gamma-hydroxybutyric acid (GHB) Baclofen Anticonvulsants The outcomes measured were (...) on potential harms are sparse and fragmented. Results do not provide sufficient evidence in favour of anticonvulsants for the treatment of alcohol withdrawal syndrome, but anticonvulsants seem to have limited side effects. There is also not enough evidence of effectiveness and safety of baclofen, because only one study consider this treatment and of GHB for which no strong differences were observed in the comparisons with placebo, benzodiazepines and anticonvulsants. Amato L, Minozzi S, Davoli M

2011 The Mental Elf

64. Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Completion Date : August 2012 Actual Study Completion Date : September 2012 Resource links provided by the National Library of Medicine related topics: related topics: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo Active Comparator: Arbaclofen Drug: Arbaclofen Other Name: STX209, R-baclofen Outcome Measures Go to Primary Outcome Measures : Aberrant Behavior Checklist-Social Withdrawal Subscale [ Time Frame: At 8 weeks of treatment ] Eligibility Criteria Go (...) Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2011 Clinical Trials

65. Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome

Comparator: STX209 5 mg BID Drug: arbaclofen 5 mg bid Other Name: R-baclofen, STX209 Active Comparator: STX209 10 mg BID Drug: arbaclofen 10 mg bid Other Name: R-baclofen, STX209 Active Comparator: STX209 10 mg TID Drug: arbaclofen 10 mg tid Other Name: R-baclofen, STX209 Placebo Comparator: Placebo Drug: Placebo tid Outcome Measures Go to Primary Outcome Measures : Aberrant Behavior Checklist-Lethargy Social Withdrawal subscale [ Time Frame: at 8 weeks of treatment ] This is a single subscale (...) Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2011 Clinical Trials

66. Alcohol withdrawal syndrome

. . www.choosingwisely.org . Retrieved 30 August 2018 . (PDF) . 2005. (PDF) from the original on 6 September 2015 . Retrieved 8 January 2016 . Liu, J; Wang, LN (April 2015). "Baclofen for alcohol withdrawal". Cochrane Database of Systematic Reviews . 4 (4): CD008502. : . . Ebadi, Manuchair (23 October 2007). "Alphabetical presentation of drugs". (2nd ed.). USA: CRC Press. p. 512. . Hodges, B; Mazur, JE (November 2004). "Intravenous ethanol for the treatment of alcohol withdrawal syndrome in critically ill patients (...) Alcohol withdrawal syndrome Alcohol withdrawal syndrome - Wikipedia Alcohol withdrawal syndrome From Wikipedia, the free encyclopedia Alcohol withdrawal syndrome , Symptoms , , sweating, vomiting, , mild fever , , Usual onset Six hours following the last drink Duration Up to a week Causes Reduction in after a period of excessive use (CIWA-Ar) Treatment , Frequency ~50% of people with upon reducing use Alcohol withdrawal syndrome is a set of symptoms that can occur following a reduction in use

2012 Wikipedia

67. Cerebral palsy in adults

. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 16 of 64the surgical procedure for implanting the pump the need for regular hospital follow-up visits to ensure optimal dosage and pump refill the risks of implanting a pump and pump-related complications (for example, battery failure or catheter leakage), which can result in baclofen withdrawal or overdose a review of 24-hour postural needs. 1.3.14 If continuous pump-administered intrathecal baclofen (...) modifiable factors identified that may be exacerbating the spasticity or dystonia and and review their physical management programme. T o find out why the committee made the recommendations on agreeing goals for treatment and initial management of spasticity and dystonia, and how they might affect practice, see rationale and impact. Spasticity Spasticity Enter Enteral muscle r al muscle relax elaxant drug tr ant drug treatments eatments 1.3.6 Consider enteral baclofen [1] as the first-line drug treatment

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

68. European Academy of Neurology guideline on the diagnosis of coma and other disorders of consciousness Full Text available with Trip Pro

to an intracranial hemorrhage from a right parietal arteriovenous malformation. After hematoma evacuation, decompressive hemicraniectomy and prolonged intensive care management, including tracheostomy, intrathecal baclofen pump placement, percutaneous endoscopic gastrostomy and placement of a ventriculo‐peritonal shunt, she remained unresponsive and was referred for multimodal consciousness evaluation 13 weeks later. Repeated neurological examinations ( n = 6) were notable for spontaneous eye opening

2020 European Academy of Neurology

69. Nonopioid Pharmacologic Treatments for Chronic Pain

reuptake inhibitor (SNRI) antidepressants in low back pain and fibromyalgia. • In the long term, evidence was too limited to draw conclusions. In general, evidence on quality of life was limited and no treatment achieved a large improvement in pain or function. • Small to moderate, dose-dependent increases in withdrawal due to adverse events were found with SNRIs duloxetine and milnacipran, anticonvulsants pregabalin and gabapentin, and NSAIDs. Large increases were seen with oxcarbazepine. NSAIDs have (...) not improve pain severity. Evidence in patients with chronic headache or sickle cell disease was too limited to draw conclusions. Adverse events categorized as “serious” were more often not reported with nonopioid drugs than placebo in patients with chronic pain, the exception being in neuropathic pain with longer duration capsaicin patch (compared with shorter duration, moderate effect). Withdrawal due to adverse events was increased with anticonvulsants, antidepressants (both moderately), NSAIDs ES-8

2020 Effective Health Care Program (AHRQ)

70. European Academy of Neurology guideline on the diagnosis of coma and other disorders of consciousness

]. Relative risk for signs of covert consciousness suggesting MCS or better Figure 2 Case example: a 27-year-old woman with a history of focal epilepsy was admitted with headache, confusion and rapid loss of consciousness due to an intracranial hemorrhage from a right parietal arteriovenous malformation. After hematoma evacuation, decompressive hemicraniectomy and prolonged intensive care management, including tracheostomy, intrathecal baclofen pump place- ment, percutaneous endoscopic gastrostomy

2020 European Academy of Neurology

71. Simplified guideline for prescribing medical cannabinoids in primary care

considering cannabinoids or opioids. ‡ Other prescribed therapies for CINV include, but are not limited to (in no particular order), serotonin antagonists (eg, ondansetron), neurokinin-1 receptor antagonists (aprepitant, fosaprepitant), corticosteroids (dexameth- asone), and dopamine antagonists (prochlorperazine, metoclopramide). § Other therapies for spasticity in MS include, but are not limited to (in no particular order), daily stretching, range-of-movement exercises, baclofen, gabapentin, tizanidine (...) was high. Across studies, the approximate risk of adverse events is 80% versus 60%, and withdrawal due to adverse events is 11% versus 3%, for cannabinoids and placebo, respectively. 12 The overall risk of adverse events is similar among varying types of medical can- nabinoids (such as nabiximols or medical marijuana). 11 Certain adverse events, relative to controls, like “feel- ing high” (35% to 70% vs 0% to 3%) and euphoria (15% vs 2%), are very common, but likely anticipated. 12 Other common adverse

2018 CPG Infobase

72. Diagnosis and management of epilepsy in adults

3.5 Hand-held video 11 3.6 Brain imaging 11 3.7 Electrocardiography 11 3.8 Genetic testing 12 4 Treatment 13 4.1 When to start antiepileptic treatment 13 4.2 Antiepileptic drug monotherapy 13 4.3 Management of drug-resistant epilepsy 14 4.4 Antiepileptic drug blood levels 16 4.5 Management of provoked seizures 17 4.6 Antiepileptic drug adverse effects 17 4.7 Antiepileptic drug withdrawal 19 4.8 Complementary therapy 20 4.9 Surgical referral 23 4.10 Management of prolonged seizures including status (...) (?-glutamyl transferase 90%, alkaline phosphatase 30%) is seen in people taking enzyme-inducing AEDs and is usually of no clinical significance. 139 Clinical symptoms have been shown to be more useful than routine monitoring of liver function in identifying the onset of serious ADRs. 137, 140 Acute psychotic reactions are seen occasionally with vigabatrin, topiramate and tiagabine, particularly in those patients with a previous history of psychiatric disease; withdrawal from the drug usually results

2018 SIGN

73. Diazepam

. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged over 2002 3. Prospective Randomized Study of Oral Diazepam and Baclofen on Spasticity in Cerebral Palsy. 27504360 2016 08 09 2016 08 09 2017 02 20 2249-782X 10 6 2016 Jun Journal of clinical and diagnostic research : JCDR J Clin Diagn Res Prospective Randomized Study of Oral Diazepam and Baclofen on Spasticity in Cerebral Palsy. RC01-5 10.7860/JCDR/2016/17067.7975 Spastic cerebral palsy (CP (...) ) is the most common form of CP. Diazepam and Baclofen are the most commonly used oral drugs to manage spasticity (...) . Study was designed to evaluate and compare their effects and safety in CP children. Study was aimed to assess and compare outcome of oral Diazepam and Baclofen in spastic cerebral palsy children in terms of extent of reduction of spasticity and side effects profile. Randomized prospective follow-up study was done for one year after giving Diazepam and Baclofen in weekly incremental doses

2018 Trip Latest and Greatest

74. Masitinib mesylate (Alsitek) - Amyotrophic Lateral Sclerosis

endurance type exercise; no other medical or surgical alternative treatment had been evaluated in randomized trials. The authors concluded that this trial was too small to determine benefit and recommended that further research was needed to test whether anti-spasticity medication (for example baclofen or dantrolene) is beneficial or causes harm by worsening muscle weakness and function. One exception to this lack of supporting evidence for symptomatic treatment in ALS is the use of non- invasive

2018 European Medicines Agency - EPARs

75. Topiramate

. But if you still have questions please contact us via jon.brassey@tripdatabase.com Top results for topiramate 1. Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol (...) consumption: a systematic review and meta-analysis PROSPERO International prospective register (...) of systematic reviews Comparative effectiveness of naltrexone, nalmefene, baclofen, acamprosate, and topiramate in the treatment of alcohol dependence or alcohol use disorders to reduce alcohol consumption: a systematic review and meta-analysis Alexandre Huneau, Renan Duprez, Clara Locher, Clément Palpacuer, Florian Naudet Citation Alexandre Huneau, Renan Duprez, Clara Locher, Clément Palpacuer, Florian

2018 Trip Latest and Greatest

76. Management of Alcohol-Related Liver Disease

in which it is physically hazardous. 9. Alcohol use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by alcohol. 10. Tolerance, as de?ned by either of the following: a. A need for markedly increased amounts of alcohol to achieve intoxication or desired effect. b. A markedly diminished effect with continued use of the same amount of alcohol. 11. Withdrawal, as manifested by either of the following (...) : a. The characteristic withdrawal syndrome for alcohol b. Alcohol (or a closely related substance, such as a benzodiazepine) is taken to relieve or avoid withdrawal symptoms. The presence of at least 2 of these criteria indicates an AUD. The severity of the AUD is de?ned as: Mild: The presence of 2 to 3 criteria Moderate: The presence of 4 to 5 criteria Severe: The presence of 6 or more criteria AUD, alcohol use disorder. JOURNAL OF HEPATOLOGY Journal of Hepatology 2018 vol. 69 j 154–181 157more than 10years before

2018 European Association for the Study of the Liver

77. Management of Decompensated Cirrhosis

and adequate diuretic dosage is de?ned as recidivant. 32 Diagnostic paracentesis is indicated in all patients with new onset ofgrade 2or 3 ascitesand in those admitted to thehospi- tal for any complication of cirrhosis. 31,32 Manual or automated neutrophil count, total protein and albumin concentration, and culture should be always assessed. A neutrophil count above 250 cells/ll denotes SBP. 33 A total protein concentration 6mmol/L)(III;1). Albumin infusion or baclofen administration (10 mg/day

2018 European Association for the Study of the Liver

79. Comprehensive Systematic Review Summary: Treatment of Tics in People with Tourette Syndrome and Chronic Tic Disorders

Severity Scale Total Tic Score than children treated with placebo, with an SMD of 0.26 (95% CI, 0.04-0.47). There were non-clinically significant decreases in blood pressure and heart rate associated with clonidine use. Abnormal ECGs occurred in two patients that returned to normal at the next visit and did not lead to withdrawal from the study. 43 Leckman 63 compared clonidine with placebo in a 12-week trial (Class II) of 47 children and adults with tics. Clonidine treatment (4 to 5 micrograms per

2019 American Academy of Neurology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>